Inovio Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 2, 2027.
| Earnings Date | 3/2/2027 |
As of September 30, 2026, Inovio Pharmaceuticals, Inc. has 110.18M shares outstanding.
| Shares Outstanding | 110.18M |
As of September 30, 2026, Inovio Pharmaceuticals, Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.57 |
| Quick Ratio | 0.54 |
| Debt / Equity | -21.47 |
| Debt / EBITDA | -0.10 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -109.84, reflecting losses generated across the asset base. The company generates approximately 2,226.52 in revenue per employee across its workforce of 112.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -109.84 |
| Revenue Per Employee | 2,226.52 |
| Employee Count | 112.00 |
As of the close on November 2, 2026, Inovio Pharmaceuticals, Inc.'s stock has declined approximately 2.26% over the past 52 weeks.
| 52-Week Price Change | -2.26% |
Over the twelve months ended September 30, 2026, Inovio Pharmaceuticals, Inc. generated 249,370.12 in revenue and converted that into -59.35M in net income, yielding earnings per share of -0.75. EBITDA reached -62.18M, while operating income came in at -64.72M.
| Revenue | 249,370.12 |
| Operating Income | -64.72M |
| Pretax Income | -59.35M |
| Net Income | -59.35M |
| EBITDA | -62.18M |
| EBIT | -64.72M |
| Earnings Per Share (EPS) | -0.75 |
As of September 30, 2026, Inovio Pharmaceuticals, Inc. holds 40.35M in cash and equivalents against 6.08M in total debt, resulting in a net debt position of -39.18M. Total book value stands at -28.30M, with working capital of -31.72M providing operational flexibility.
| Cash & Cash Equivalents | 40.35M |
| Total Debt | 6.08M |
| Net Debt | -39.18M |
| Equity (Book Value) | -28.30M |
| Book Value Per Share | -0.26 |
| Working Capital | -31.72M |
Inovio Pharmaceuticals, Inc. produced -61.97M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -106,325.25 in capital expenditures, free cash flow totaled -62.08M - equivalent to -0.78 per share.
| Operating Cash Flow | -61.97M |
| Capital Expenditures | -106,325.25 |
| Free Cash Flow | -62.08M |
| FCF Per Share | -0.78 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -25,953.76 and net profit margin of -23,798.90 provide insight into operational efficiency.
| Operating Margin | -25,953.76 |
| Pretax Margin | -23,798.90 |
| Profit Margin | -23,798.90 |
| EBITDA Margin | -24,934.34 |
Inovio Pharmaceuticals, Inc.'s most recent stock split took place on January 25, 2024 with a 12:1 split ratio.
| Last Split Date | 1/25/2024 |
| Split Ratio | 12:1 |